Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30664602 | 1.00 | LMNA (0.48) | LMNAALDH1A1POLBGAATHRB | |
| SCHEMBL6597479 | 0.88 | CYP1A2 (0.47) | LMNAALDH1A1POLBGAATHRB | |
| SCHEMBL22165300 | 0.86 | MEN1 (0.49) | LMNAALDH1A1POLBGAATHRB | |
| SCHEMBL17827840 | 0.85 | ALDH1A1 (0.47) | LMNAALDH1A1POLBGAATHRB | |
| SCHEMBL502591 | 0.84 | PDGFRB (0.53) | LMNAALDH1A1POLBHTTL3MBTL1 | |
| SCHEMBL1441025 | 0.83 | ALDH1A1 (0.50) | LMNAALDH1A1POLBGAATHRB | |
| SCHEMBL14439930 | 0.82 | POLB (0.50) | LMNAALDH1A1POLBTHRBPDGFRB | |
| SCHEMBL1817138 | 0.82 | POLB (0.47) | LMNAALDH1A1POLBGAAHTT | |
| SCHEMBL9156278 | 0.82 | ALDH1A1 (0.58) | LMNAALDH1A1GAATHRBHTT | |
| SCHEMBL31444647 | 0.82 | LMNA (0.51) | LMNAALDH1A1POLBGAATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3573972-B1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2026-01-14 | — | — | EP | disclosed |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| US-20250340556-A1 | PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF | SOLTEGO INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4526307-A1 | PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF | Soltego, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2024-08-01 | — | — | US | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| WO-2023225097-A1 | PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF | SOLTEGO, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20160083392-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BEIGENE, LTD. (KY) | 2016-03-24 | — | — | US | disclosed |
| US-20160083392-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BEIGENE, LTD. (KY) | 2016-03-24 | — | — | US | disclosed |
| EP-2989106-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | Beigene, Ltd. (KY) | 2016-03-02 | — | — | EP | disclosed |
| US-20150259354-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BEIGENE, LTD. (KY) | 2015-09-17 | — | — | US | disclosed |
| US-20150259354-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BEIGENE, LTD. (KY) | 2015-09-17 | — | — | US | disclosed |
| US-20150259354-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BEIGENE, LTD. (KY) | 2015-09-17 | — | — | US | disclosed |
| US-20140336252-A1 | NOVEL COMPOUND AS KCNQ POTASSIUM CHANNEL AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2014-11-13 | — | — | US | disclosed |
| WO-2014173289-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014173289-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2014-10-30 | — | — | WO | disclosed |
| WO-2011130741-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340556-A1 | PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF | SIK2, SIK1, SIK3 | LMNA 3188/4885ALDH1A1 2257/4885POLB 1297/4885 |
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | LMNA 4691/4885ALDH1A1 3106/4885POLB 2407/4885 |
| US-20150259354-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BTK, WEE1, LYN | LMNA 4466/4885ALDH1A1 3907/4885POLB 4332/4885 |
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | LMNA 2098/4885ALDH1A1 2596/4885POLB 651/4885 |
| US-20160083392-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BTK, WEE1, LYN | LMNA 4466/4885ALDH1A1 3907/4885POLB 4332/4885 |
| US-20140336252-A1 | NOVEL COMPOUND AS KCNQ POTASSIUM CHANNEL AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF | KCNQ1, KCNQ4, KCNQ5 | LMNA 1631/4885ALDH1A1 1888/4885POLB 2976/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | LMNA 2098/4885ALDH1A1 2596/4885POLB 651/4885 |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | LMNA 4691/4885ALDH1A1 3106/4885POLB 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.